ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice – Contact Levi & Korsinsky

Important Notice Regarding Alleged Payer Access and Reimbursement Misrepresentations: the lawsuit contends Ardelyx pointed investors toward $1.75 billion in combined peak sales while payer utilization-management barriers were allegedly restricting patient starts for IBSRELA and XPHOZAH.

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. (NASDAQ: ARDX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between January 13, 2025 and August 6, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Throughout the Class Period, Ardelyx pointed investors toward $1.75 billion in combined peak annual U.S. net product sales for its two commercial medicines. ARDX shares then fell approximately 18%, a single-day decline of $0.87 per share, after the Company announced a reduction in full-year 2026 IBSRELA revenue guidance and the withdrawal of its long-term XPHOZAH revenue guidance on August 6, 2026. Applications to serve as lead plaintiff must be filed by November 16, 2026.

The Alleged Payer Access Disclosure Failure

Revenue at Ardelyx depends on prescriptions being written and then actually filled, which for both of its products requires clearing insurer prior authorization. According to the lawsuit, payer utilization-management processes grew materially more restrictive during the Class Period, with more stringent prior authorization and step edit requirements slowing new-patient starts and delaying prescription fulfillment. The complaint alleges that investors were instead told the patient-access strategy was working.

How Alleged Access Barriers Affected the Revenue Outlook

The lawsuit contends that the fiscal 2026 revenue outlook and the long-term growth targets for XPHOZAH and IBSRELA rested on access assumptions that were allegedly already being undercut by conditions inside the reimbursement channel. When the Company cited significantly increased payer utilization-management processes and uncertainty regarding future growth, the long-term XPHOZAH target was withdrawn outright, and shareholders who purchased at allegedly inflated prices absorbed the loss.

Key Payer Access Allegations for Shareholders

• Combined peak sales expectations of $1.75 billion, consisting of $750 million for XPHOZAH and more than $1 billion for IBSRELA, were reaffirmed to investors during the Class Period.
• Increasing payer-related access and reimbursement barriers affecting patient access were allegedly not disclosed.
• More stringent prior authorization and step edit requirements allegedly slowed new-patient starts and delayed fulfillment.
• Management allegedly represented an ability to execute the commercial strategy and overcome patient-access barriers.
• The August 6, 2026 announcement reduced full-year 2026 IBSRELA guidance and withdrew long-term XPHOZAH guidance, citing evolving market dynamics.
• Claims are asserted under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5 in the United States District Court for the District of Massachusetts.
  
  

"This case presents important questions about how payer access and reimbursement developments must be disclosed in the pharmaceutical sector. The complaint alleges that shareholders received long-term sales targets at a time when utilization-management requirements were already restricting new-patient starts." -- Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the ARDX Lawsuit

Q: Who is eligible to join the ARDX investor lawsuit? A: Investors who purchased ARDX stock or securities between January 13, 2025 and August 6, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did ARDX stock drop? A: Shares fell approximately 18%, a decline of $0.87 per share, after the Company disclosed a reduction in its full-year 2026 IBSRELA revenue guidance and the withdrawal of its long-term XPHOZAH revenue guidance. Investors who purchased shares during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.

Q: What court was the ARDX class action filed in? A: The case was filed in the United States District Court for the District of Massachusetts, governed by the Private Securities Litigation Reform Act of 1995.

Q: What do ARDX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my ARDX shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.